Canagliflozin – A Novel Oral Hyperglycemic Agent in The Fight Against Diabetic Mellitus

Journal Title: IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) - Year 2017, Vol 16, Issue 12

Abstract

Canagliflozin, is a first-in-class,oral hypoglycemic drug to be approved by US FDA, that acts through inhibition of sodium glucose co- transporters in the renal tubules, resulting in glucosuria. Clinical trials with canagliflozin have shown that it causes consistent dose-dependent reduction in HbA1c. The drug has a risk of causing genito-urinary infections& amputations in patients with diabetic foot ulcers. This article summarizes the current knowledge regardingcanagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus

Authors and Affiliations

S. Melina. I. Sahay, DamalKandadai Sriram, Melvin George

Keywords

Related Articles

“Risk Factor Analysis of Young Stemi Patients in A Tertiary Care Centre”

Introduction:- Acute STEMI is one of the leading cause of death in the world. It is less common in younger individuals ( less than 45 yrs). But it is of more clinical importance in younger patients, because it can cause...

Nerve Conduction Response by Using Low-Dose Oral Steroid in the Treatment of Carpal Tunnel Syndrome (CTS)

Introduction: Now a day’s Carpal tunnel syndrome is the most common entrapment neuropathy. The carpal tunnel syndrome (CTS) is a medical condition that caused by compression of the median nerve as it travels through the...

A Clinical Study of Multi Nodular Goitre in a Tertiary Care Unit

The aim of study is to study the clinical presentations, surgical management and its outcome and complications associated with Multi nodular goitre patients.This randomized prospective study includes 50 patients with mul...

Clinical Trends of Pediatric Viral Infections- A Clinico Epidemiologic Study

Background: Cutaneous infections form an important component of pediatric dermatology. Pediatric viral infections are common and probably increasing in incidence over the last few decades because of increase in incidence...

Role of Modified Triple Tests in Early Detection of Malignancies in Breast Lumps

Introduction :Breast diseases are at a rising trend in recent years among young women. Many cancers are diagnosed at advanced stages. Carcinoma breast that too invasive ductal variety is the most commonest of all. Aims a...

Download PDF file
  • EP ID EP251473
  • DOI 10.9790/0853-1612099296
  • Views 110
  • Downloads 0

How To Cite

S. Melina. I. Sahay, DamalKandadai Sriram, Melvin George (2017). Canagliflozin – A Novel Oral Hyperglycemic Agent in The Fight Against Diabetic Mellitus. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 16(12), 92-96. https://europub.co.uk/articles/-A-251473